Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 10-Week group program help clear Post-COVID brain fog?

NCT ID NCT07821385

Symptom relief Sponsor: Danderyd Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Many people who had COVID-19 continue to struggle with fatigue, memory problems, and difficulty managing daily tasks. This study follows 120 adults with these symptoms who join a 10-week group rehabilitation program at a Swedish hospital. The program brings together occupational therapists, psychologists, physiotherapists, physicians, and social workers to offer education, discussion, and physical activity. Researchers want to learn which activities patients most want to improve and whether the program changes how they rate their daily performance, health, and life satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a 10-week interprofessional group rehabilitation program combining cognitive training, education, and physical activity
What this could lead to
If the program helps, it could give clinics a clearer model for treating post-COVID brain fog and fatigue, and help patients return to work and daily activities.
What could go wrong
This is a small observational study at one Swedish clinic, so results may not apply to other patients or settings. The program may not improve symptoms for everyone, and the study cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

120 people

The number who actually took part.

Started

Aug 2021

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged 18-65 with persistent cognitive symptoms and fatigue following confirmed or strongly suspected COVID-19 infection, who have undergone assessment at the Cognitive Post-COVID Clinic at Danderyd Hospital and subsequently completed a team evaluation prior to participation in interdisciplinary rehabilitation. During the assessment, it is determined whether the patient needs and can benefit from rehabilitation.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals aged 18 and older with confirmed COVID-19 or with a very likely prior COVID-19 infection. * Newly developed cognitive impairments or cognitive fatigue. --A clear temporal link between COVID-19 onset and symptom onset, with symptoms affecting return to previous activities/occupation. * The acute phase of illness ended at least 3 months earlier. * Basic investigations for specific differential diagnoses must have been completed at the initial clinic visit, according to "COVID-19 - persistent symptoms" (see viss.nu), excluding anemia, thyroid dysfunction, and alcohol overconsumption. Assessment for depression. * Medication review and relevant adjustments carried out with regard to the patient's symptoms Exclusion Criteria: * Predominant recurrent and/or fluctuating infectious symptoms, circulatory, respiratory, or cardiac problems. * Other symptoms due to organ failure that should primarily be managed by an organ specialist. * Severe psychiatric illness, including depression with pronounced cognitive symptoms. * Cognitive impairments primarily related to neurodegenerative disease or substance misuse, e.g., alcohol-related dementia, Korsakoff's dementia, or other dementia disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-COVID condition are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Personal Satisfaction post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postcovid

Contacts and locations

Locations

  • Department of Rehabilitaiton Medicine Stockholm

    Stockholm, 18288, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.